Aztreonam is a synthetic bactericidal monobactam antibiotic. It inhibits bacterial cell wall synthesis by blocking peptidoglycan crosslinking. The inhibition of bacterial cell wall synthesis occurs due to a high affinity of Aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, Aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that Aztreonam interferes with an autolysin inhibitor.
Azonam IM/IV Injection 1 gm
Adults: The usual dose of Aztreonam is 3 to 4 gm daily (maximum recommended dose is 8 gm daily). The dosage and route of administration should be determined by the susceptibility of the causative organisms, severity of infection and the condition of the patient. In case of Pseudomonas aeruginosa infections, 2 gm every 6 or 8 hours is recommended.
Children: The usual dosage for patients older than one week is 30 mg/kg/dose every 6 or 8 hours. For severe infections in patients 2 years of age or older, 50 mg/kg/dose every 6 or 8 hours is recommended.Dosage information is not yet available for new-born less than 1 week old.
Dosage Guideline for adult:
Urinary tract infections: 500 mg or 1 gm; 8 or 12 hourly
Moderately severe systemic infections: 1 g or 2 gm; 8 or 12 hourly
Severe systemic or life-threatening infections: 2 gm; 6 or 8 hourly
Maximum recommended dose is 8 gm/ day.
Dosage Guideline or pediatric:
Mild to moderate infections: 30 mg/kg; 8 hourly
Moderate to severe infections (2 years or older): 50 mg/kg; 6 or 8 hourly
Maximum recommended dose is 120 mg/ kg/ day.